Novalar Makes OraVerseÂ® Product Donation to National Children’s Oral Health Foundation
SAN DIEGO, Nov. 30, 2010 /PRNewswire/ — Novalar Pharmaceuticals, Inc., a specialty pharmaceutical company focused in dental, today announced that it has donated over $100,000 worth of OraVerseÃ‚® product to National Children’s Oral Health Foundation (NCOHF). The NCOHF Affiliate network is a consortium of more than 60 of America’s finest not-for-profit oral health programs dedicated to eliminating pediatric dental disease by offering quality, comprehensive dental services to the underserved children who need them most.
“We are extremely pleased to make this donation and to be collaborating with NCOHF in its efforts to increase access to dental care for pediatric patients,” said Donna Janson, President & CEO of Novalar. “Through this donation program, dentists within the network may effectively treat their patients with local anesthetics without the resulting lingering and unnecessary soft-tissue numbness, allowing them to more quickly return to their normal daily activities.”
OraVerse is a breakthrough that reverses unwanted lingering numbness after routine dental procedures where a local anesthetic containing a vasoconstrictor was used. OraVerse is indicated for reversal of the soft-tissue anesthesia, i.e., anesthesia of the lip and tongue, and the associated functional deficits resulting from an intraoral submucosal injection of a local anesthetic containing a vasoconstrictor. OraVerse is not recommended for use in children less than 6 years of age or weighing less than 15 kg (33 lbs). For more information visit www.oraverse.com.
Important Safety Information
In clinical trials, the most common adverse events with OraVerse (phentolamine mesylate) vs. control were post procedural pain (6% vs. 6%), injection site pain (5% vs. 4%), tachycardia (5% vs. 6%), bradycardia (2% vs. 0.3%) and headache (3% vs. 4%). Following parenteral use of phentolamine in non-dental indications, myocardial infarction and cerebrovascular spasm and occlusion have been reported, usually in association with marked hypotensive episodes producing shock-like states. Although such effects are uncommon with OraVerse, clinicians should be alert to the signs and symptoms of tachycardia and cardiac arrhythmias, particularly in patients with a history of cardiovascular disease, as these symptoms may occur with the use of phentolamine or other alpha-adrenergic blocking agents.
Novalar is a specialty pharmaceutical company that partners directly with dental professionals to enrich the patient experience. The company is uniquely positioned to develop targeted oral pharmaceutical products and translate the full value of these novel solutions to clinical practice. For more information, please visit www.novalar.com.
SOURCE Novalar Pharmaceuticals, Inc.